Insider Selling: Vericel Co. (NASDAQ:VCEL) Insider Sells $24,525.00 in Stock

Vericel Co. (NASDAQ:VCEL) insider Jonathan Siegal sold 545 shares of the business’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $45.00, for a total value of $24,525.00. Following the transaction, the insider now directly owns 1,033 shares in the company, valued at $46,485. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Vericel Trading Up 8.7 %

Shares of VCEL opened at $49.41 on Friday. Vericel Co. has a 12 month low of $30.18 and a 12 month high of $53.05. The firm’s 50 day moving average is $46.53 and its 200-day moving average is $45.16. The stock has a market capitalization of $2.40 billion, a PE ratio of -4,936.06 and a beta of 1.70.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $51.28 million for the quarter, compared to analyst estimates of $49.07 million. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The company’s revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.16) EPS. Equities research analysts predict that Vericel Co. will post 0.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VCEL. MCF Advisors LLC boosted its stake in shares of Vericel by 86.1% in the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 223 shares in the last quarter. Swiss National Bank increased its stake in shares of Vericel by 0.4% in the first quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock valued at $4,656,000 after buying an additional 400 shares during the period. CWM LLC raised its position in shares of Vericel by 319.0% during the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 504 shares during the last quarter. Arcadia Investment Management Corp MI bought a new stake in Vericel in the first quarter valued at approximately $27,000. Finally, Gotham Asset Management LLC increased its position in Vericel by 3.6% during the 3rd quarter. Gotham Asset Management LLC now owns 15,311 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 538 shares during the period.

Analyst Ratings Changes

Several equities analysts have commented on VCEL shares. TD Cowen initiated coverage on shares of Vericel in a report on Thursday, June 20th. They issued a “buy” rating and a $55.00 price objective on the stock. HC Wainwright increased their price target on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Truist Financial restated a “buy” rating and set a $54.00 price objective on shares of Vericel in a report on Tuesday, March 26th. Finally, StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Friday, June 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.17.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.